STM2457, a compound that reduces m6A modification by suppressing the METTL3/METTL14 complex, has shown good antitumor effects in malignant tumors including leukemia, cholangiocarcinoma, and osteosarcoma and has shown potential in reversing liver and lung cancer resistance [26,46–48]. This evidence concerns the gene METTL3 and cancer.